Quote:
Originally Posted by OyCrumbler
Oh yea, they both have significant challenges for sure. I do think Rivian's currently at much steadier footing than Lucid is.
The banks care a lot about projections and it's a large factor in how things like loan terms are determined. They do indeed need to tell these things to the bank or other similar financial institutions as they raise funding. That's essentially their runway and the hope is that the runway they secure is enough to get the company up and working well at a profit while rewarding rewarding earlier investors. That's essentially how Tesla and a host of other successful automakers of the last few decades were able to go from hemorrhaging money during their ramp up to becoming comfortably profitable year after year.
|
Yes, for the startups, it's essentially a race to establish sufficient revenues and refine the business sufficiently to be profitable - before the early investors money runs out. And Ford and GM for example are not accidentally landing in their situation of having the ICE vehicle revenues subsidize the EV division until that can become profitable - that's their business model. A lot of environmentalists have thrown huge amounts of dung at them because they didn't just abandon ICE vehicles immediately and make EVs, but that would have been a disaster for them. You still need a workable business model.
I am in the drug development business - where it typically takes 10 years for a development program to begin commercial sales, and over 90% of programs fail. You really need well educated investors who are also true believers in the company, because even if you are good, and lucky as well, it will still take many years for the ideas to come to fruition, and for all those years, a startup is just spending investors' money, with no drug revenues. And if results in early clinical trials are promising, the stock price zooms up and you have more cash to keep developing, and can easily do another fund raise through the market if needed. But if early results are disappointing at any point, then the stock price plummets and even if you have another program(s). it's hard to get more money and you're looking at make or break next trials, which you may run out of money to actually conduct, and even though there are still real possibilities, the company is forced to close its doors without fully exploring it's R&D potential. Happens all the time.